Bellevue Group AG
Q1 2020 13F-HR Holdings
Net value change ($000)
-1,150,809
(-18.2%)
New positions
16
Sold out positions
17
Turnover %
2.1%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2019
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| BDTX | 33,184 | NEW |
| FATE | 33,099 | 2043.1% |
| MRNA | 21,778 | 22.6% |
| GW PHARMACEUTICALS PLC | 20,806 | 1776.8% |
| Molecular Templates, Inc. | 20,562 | 113.5% |
| AMGN | 16,947 | 174.2% |
| GILD | 10,251 | 1857.1% |
| DXCM | 10,119 | 58.9% |
| KZR | 9,124 | 146.7% |
| HOLX | 6,262 | 45.8% |
Top Reduces (Value $000, Stocks/ETFs)
| IONS | -113,177 | -22.2% |
| ESPR | -110,982 | -41.1% |
| NBIX | -74,585 | -20.9% |
| BMY | -66,915 | -49.9% |
| INCY | -63,688 | -20.7% |
| Sage Therapeutics, Inc. | -53,758 | -56.9% |
| Radius Health, Inc. | -49,175 | -35.1% |
| AGIO | -48,852 | -26.1% |
| INTERCEPT PHARMACEUTICALS, INC. | -43,986 | -49.6% |
| ALGN | -42,444 | -54.6% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
7
(0.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|